Insmed (INSM) Change in Receivables (2010 - 2026)
Insmed (INSM) posted quarterly Change in Receivables of $38.2 million for Q1 2026, up 812.37% year-over-year from $4.2 million in Q1 2025, and down 50.6% quarter-over-quarter from $77.3 million in Q4 2025.
Insmed (INSM) Change in Receivables (2010 - 2026) Analysis & Trends
Insmed's Change in Receivables history runs 12 years deep, the most recent figure standing at $38.2 million for Q1 2026.
- In Q1 2026, Change in Receivables rose 812.37% year-over-year to $38.2 million; the TTM figure through Mar 2026 stood at $131.9 million (up 1152.69% YoY), while the FY2025 annual figure was $88.3 million, up 582.86% from the prior year.
- Change in Receivables for Q1 2026 stood at $38.2 million, down from $77.3 million in the prior quarter.
- The five-year high for Change in Receivables was $77.3 million in Q4 2025, with the low at -$5.4 million in Q1 2025.
- The 5-year median for Change in Receivables is $4.0 million (2024), against an average of $9.3 million.
- The sharpest annual moves came in 2024 and 2025: Change in Receivables slumped 443.6% in 2024, then soared 29117.14% in 2025.
- Insmed's Change in Receivables stood at $983000.0 in 2022, then surged by 361.34% to $4.5 million in 2023, then soared by 160.57% to $11.8 million in 2024, then soared by 554.14% to $77.3 million in 2025, then plunged by 50.6% to $38.2 million in 2026.
- Business Quant data shows INSM's Change in Receivables at $38.2 million in Q1 2026, $77.3 million in Q4 2025, and $10.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.16 Mn |
| Jun 30, 2026 | 37.16 Mn |
| Mar 31, 2026 | 38.19 Mn |
| Mar 31, 2026 | 38.19 Mn |
| Dec 31, 2025 | 77.30 Mn |
| Dec 31, 2025 | 77.30 Mn |
| Sep 30, 2025 | 10.23 Mn |
| Sep 30, 2025 | 10.23 Mn |
| Jun 30, 2025 | 6.14 Mn |
| Jun 30, 2025 | 6.14 Mn |
| Mar 31, 2025 | -5.36 Mn |
| Mar 31, 2025 | -5.36 Mn |
| Dec 31, 2024 | 11.82 Mn |
| Dec 31, 2024 | 11.82 Mn |
| Sep 30, 2024 | 35,000.00 |
| Sep 30, 2024 | 35,000.00 |
| Jun 30, 2024 | 4.04 Mn |
| Jun 30, 2024 | 4.04 Mn |
| Mar 31, 2024 | -2.96 Mn |
| Mar 31, 2024 | -2.96 Mn |